Overview

A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Subjects With Major Depressive Disorder

Status:
Completed
Trial end date:
2020-03-17
Target enrollment:
Participant gender:
Summary
This study is a phase 3, multicenter, double-blind, randomized, placebo-controlled study evaluating the efficacy of SAGE-217 in the treatment of adult subjects with major depressive disorder
Phase:
Phase 3
Details
Lead Sponsor:
Sage Therapeutics